132 related articles for article (PubMed ID: 38710856)
1. Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.
Snyder GL; Li P; Martin T; Zhang L; Yao W; Zheng H; Maguire DR; Gerak LR; Vanover KE; France CP; Davis R
Psychopharmacology (Berl); 2024 Jul; 241(7):1477-1490. PubMed ID: 38710856
[TBL] [Abstract][Full Text] [Related]
2. Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of
Gerak LR; Minervini V; Latham E; Ghodrati S; Lillis KV; Wooden J; Disney A; Husbands SM; France CP
J Pharmacol Exp Ther; 2019 Nov; 371(2):507-516. PubMed ID: 31439807
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-
Yadlapalli JSK; Bommagani SB; Mahelona RD; Wan A; Gannon BM; Penthala NR; Dobretsov M; Crooks PA; Fantegrossi WE
Pharmacol Res Perspect; 2018 Jul; 6(4):e00403. PubMed ID: 29930811
[TBL] [Abstract][Full Text] [Related]
4. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
Dodu JC; Moncayo RK; Damaj MI; Schlosburg JE; Akbarali HI; O'Brien LD; Kendall DA; Wu Z; Lu D; Lichtman AH
J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
[TBL] [Abstract][Full Text] [Related]
5. Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders.
Li P; Zhang Q; Zheng H; Qiao Y; Snyder GL; Martin T; Yao W; Zhang L; Davis RE
J Med Chem; 2024 Jun; 67(11):9355-9373. PubMed ID: 38805667
[TBL] [Abstract][Full Text] [Related]
6. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal.
Aley KO; Levine JD
J Neurosci; 1997 Jan; 17(2):735-44. PubMed ID: 8987795
[TBL] [Abstract][Full Text] [Related]
7. Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.
Wiebelhaus JM; Walentiny DM; Beardsley PM
J Pharmacol Exp Ther; 2016 Jan; 356(1):43-52. PubMed ID: 26491062
[TBL] [Abstract][Full Text] [Related]
8. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
9. OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.
Maguire DR; Gerak LR; Cami-Kobeci G; Husbands SM; France CP; Belli B; Flynn P
J Pharmacol Exp Ther; 2020 Feb; 372(2):205-215. PubMed ID: 31748404
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
11. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
12. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
13. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
Withey SL; Spealman RD; Bergman J; Paronis CA
J Pharmacol Exp Ther; 2019 Nov; 371(2):544-554. PubMed ID: 31413139
[TBL] [Abstract][Full Text] [Related]
14. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of μ-opioid receptor agonist/δ-opioid receptor antagonist peptidomimetics following acute and repeated administration.
Anand JP; Kochan KE; Nastase AF; Montgomery D; Griggs NW; Traynor JR; Mosberg HI; Jutkiewicz EM
Br J Pharmacol; 2018 Jun; 175(11):2013-2027. PubMed ID: 29352503
[TBL] [Abstract][Full Text] [Related]
16. Selective M
Teal LB; Bubser M; Duncan E; Gould RW; Lindsley CW; Jones CK
Neuropharmacology; 2023 Apr; 227():109424. PubMed ID: 36720403
[TBL] [Abstract][Full Text] [Related]
17. Validation and characterization of oxycodone physical dependence in C57BL/6J mice.
Carper M; Contreras KM; Walentiny DM; Beardsley PM; Damaj MI
Eur J Pharmacol; 2021 Jul; 903():174111. PubMed ID: 33901461
[TBL] [Abstract][Full Text] [Related]
18. The antagonistic activity profile of naloxone in μ-opioid receptor agonist-induced psychological dependence.
Nakamura A; Yasufuku K; Shimada S; Aritomi H; Furue Y; Chiba H; Muramoto M; Takase K; Koike K; Matsumoto T; Shimada T; Watari R; Matsuzaki T; Asaki T; Kanemasa T; Fujita M
Neurosci Lett; 2020 Sep; 735():135177. PubMed ID: 32569809
[TBL] [Abstract][Full Text] [Related]
19. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
20. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
Austin Zamarripa C; Edwards SR; Qureshi HN; Yi JN; Blough BE; Freeman KB
Drug Alcohol Depend; 2018 Nov; 192():158-162. PubMed ID: 30261403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
